A Rollover Study for Participants Previously Enrolled in a Genentech and/or F. Hoffman-La Roche Sponsored Study

This study is for patients who are already in a specific cancer treatment study run by Genentech or F. Hoffman-La Roche. You can join if your current trial treatment is still helping you and your doctor thinks it's suitable to continue. You would typically move into this new study very soon after your original study treatment ends, usually within seven days.

However, you can't join if the treatment you're receiving is already easily available in your country for your type of cancer. Also, if your original study told you to stop the treatment for any reason, or if you've had a serious side effect that hasn't gotten better, you won't be able to join this extension study. You also can't be taking part in another cancer study at the same time, apart from the one you're rolling over from.

If you join this study, you will continue to receive the same study medication (or combination of medications) that you were getting in your previous Genentech or F. Hoffman-La Roche cancer study. The visits and assessments will likely be similar to what you've experienced before, allowing your doctors to carefully monitor your health and how the treatment is working. This is an ongoing treatment study, so the duration will depend on how well you are responding to the treatment and if your doctor believes it is still the best option for you. You won't be expected to take any additional cancer treatments while in this study, other than what's specifically allowed by the study rules.